Surabhi Dangi-Garimella, PhD

Imbruvica, developed by Janssen for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who are unsuitable to receive chemo-immunotherapy, has been rejected by UK’s National Institute of Health and Care Excellence.

The pharmaceutical industry needs to rethink its approach to packaging cancer drugs into a one-size vial to avoid drug wastage and save over $1.7 billion in 2016.

The event saw participation by patient advocacy groups, health economists, health policy researchers, and patient advocacy groups-the primary interest of the participants was to identify the healthcare-associated economic hardships faced by patients and their caregivers across therapeutic areas and discuss potential solutions that could help alleviate some of this burden.

Research led by investigators at the Vanderbilt University Medical Center has concluded that adjuvant chemotherapy improved survival compared with patients who received adjuvant chemoradiation in pancreatic cancer.

A new proposal from researchers at MIT and Dana-Farber offers a remedy for patients to cover high healthcare costs: securitized consumer healthcare loans.

A new study questions the maximum-tolerated-dose approach in cancer.

A collaborative study conducted across cancer treatment centers in the United States has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39 years.

Survival in children with acute lymphoblastic leukemia could be significantly influenced by their family’s socioeconomic status, a new study published in Pediatric Blood and Cancer has found.

A new report by the American Cancer Society points to disparities in cancer survival between whites and blacks for certain cancers, although the reasons for these differences remain unconfirmed.

The online tool includes worksheets for the most commonly used cancer treatment protocols that care providers can directly access through the electronic health record.

The supplemental new drug application submitted by Pfizer, the drug's manufacturer, included phase 3 results from the PALOMA-3 trial.

Support from at least 60 senators during today's procedural vote will ensure a final confirmation vote for Robert Califf, MD, likely Tuesday.

Two studies presented at the ongoing 2016 Multidisciplinary Head and Neck Cancer Symposium report on financial hurdles faced by patients diagnosed with head and neck cancer that result in lifestyle modifications, advanced disease, and worse outcomes.

Population health, healthcare value, innovations in healthcare, cost of care-these were just some of the topics discussed at the meeting.

A new study, published in Nature Communications, has delineated a mechanism that could help explain the resistance that is emerging with the new immuno-oncology agents such as PD-1 and PD-L1.

A Task Force composed of gastroenterology specialists, with a special interest in colorectal cancer, has released updated recommendations urging post-operative colonoscopy instead of endoscopy to improve survival.

CMS, in collaboration with a working group of national organizations, has developed a set of Medical Oncology Measures to improve quality of care and avoid redundancy for providers of care.

A noninvasive colorectal cancer screening test manufactured by Exact Sciences, which received CMS coverage within months of its FDA approval, is not included under Humana’s coverage policy

Inhibiting the PIGF/VEGFR-1 signaling regressed tumor growth in obese, but not in lean mice, the author report.

A study published in Cancer Epidemiology, Biomarkers & Prevention has identified geographic and ethnic factors as an important determinant of vaccinating against the human papillomavirus.

Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.

A summary of updated breast cancer screening guidelines, MEDPAC recommendations for 340B, and disparity in survival of young patients with Hodgkin lymphoma.

A study published in JAMA Oncology found that the knowledge of genetic risk influenced surgical treatment decisions in women younger than 40 years who were diagnosed with breast cancer.

At the annual JP Morgan Healthcare Conference, Patrick Soon-Shiong, MD, introduced Cancer MoonShot, his vision for a coalition to improve cancer outcomes. His claims on federal support for the project, however, stirred some controversy.

Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.

The cost issues with immuno-oncology agents are real, but so is the value that they bring to the table. How can we improve access to these agents at a reasonable cost?

Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.

Widespread adoption of telemedicine has not been documented, and a session at the 2016 National Health Policy Conference hosted by AcademyHealth addressed some of the current challenges.

The panel members that have proposed the recommendations have found clinical utility for several genomic tests to guide clinical decision in women with early stage breast cancer.

Using data gathered from the National Ambulatory Medical Care Survey, the authors of a JAMA Internal Medicine study identified a significant decrease in PSA testing referrals by primary care physicians compared with urologists.